PEAK6’s Protagonist Therapeutics PTGX Stock Holding History

PEAK6’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9,000	Closed	-$347K	–	3495
2024 Q4	$347K	Buy	+9,000	New	+$392K	﹤0.01%	2330

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PEAK6's PTGX Position: Q1 2025 in Review

PEAK6 sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 9,000 shares — an estimated $347K sold.

PEAK6 first reported a position in PTGX in Q4 2024 and held it in 1 quarter. The position peaked at $347K in Q4 2024. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

PEAK6 reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
PEAK6 sold 9,000 Protagonist Therapeutics shares in Q1 2025, an estimated $347K.
PEAK6 first reported a position in Protagonist Therapeutics in Q4 2024 and held it in 1 quarter.
PEAK6's Protagonist Therapeutics position peaked at $347K in Q4 2024.
275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on PEAK6's 13F filing for Q1 2025, filed 14 May 2025.